IsoRay's Cesium-131 Cancer Fighting Portfolio was on Display at the American Association of Physicists in Medicine (AAPM) Convention
8:30 am ET July 16, 2015 (Market Wire) Print
IsoRay Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced it participated at the American Association of Physicists in Medicine by hosting a private dinner and booth display. The annual AAPM meeting took place July 12-16, 2015 at the Anaheim Convention Center in Anaheim, California.
IsoRay CEO Dwight Babcock commented, "IsoRay is pleased to once again participate at the AAPM annual meeting. At this venue, we have a great opportunity to meet physicists from major institutions who are instrumental in the dosimetry planning for the use of Cesium-131 for a specific patient's treatment. With peer reviewed publications continuing to show the positive results patients are achieving with the use of Cesium-131, physicists are increasingly becoming interested in the innovative alternative our Cesium-131 products offer the patient."
IsoRay's various products, including Cesium-131 seeds, sutured seeds, stranded mesh and the GliaSite(R) radiation therapy system, give physicians the ability to directly place a specified dosage of radiation in areas where cancer is most likely to remain after completion of a tumor removal or by placing seeds within the prostate. The ability to precisely place a specified dose of radiation means there is less likelihood for damage to occur to healthy surrounding tissue compared to other alternative treatments. IsoRay's cancer fighting products diminish the ability of the tumor to recur, resulting in important benefits for patients in longevity as well as quality of life. Cesium-131 is now being used for the treatment of a wide array of cancers throughout the body including brain, lung, head and neck, chest wall, prostate and gynecologic cancers.
About IsoRay IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc. is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of GliaSite(R) and Cesium-131 by visiting www.isoray.com. Join us on Facebook/Isoray. Follow us on Twitter @Isoray.
Safe Harbor Statement Statements in this news release about IsoRay's future expectations, including: the advantages of our products and their delivery systems, whether interest in and use of our products will increase or continue, whether awareness and adoption of our products in the medical community will continue or increase, whether peer-reviewed publications of treatment results using our products will report favorable results, and all other statements in this release, other than historical facts, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). This statement is included for the express purpose of availing IsoRay, Inc. of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as physician acceptance, training and use of our products, our ability to successfully manufacture, market and sell our products, our ability to manufacture our products in sufficient quantities to meet demand within required delivery time periods while meeting our quality control standards, our ability to enforce our intellectual property rights, whether additional studies are released and support the conclusions of past studies, whether ongoing patient results with our products are favorable and in line with the conclusions of clinical studies and initial patient results, patient results achieved when our products are used for the treatment of cancers and malignant diseases beyond prostate, successful completion of future research and development activities, whether we, our distributors and our customers will successfully obtain and maintain all required regulatory approvals and licenses to market, sell and use our products in its various forms, continued compliance with ISO standards as audited by BSI, the success of our sales and marketing efforts, changes in reimbursement rates, changes in laws and regulations applicable to our products, and other risks detailed from time to time in IsoRay's reports filed with the SEC. Unless required to do so by law, the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
IsoRay Medical
Info@Isoray.com
(509) 375-1202
SOURCE: IsoRay, Inc.
